MPWT
KLRS

MassMutual Private Wealth & Trust’s Kalaris Therapeutics KLRS Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3
Closed -$1K – 1891
2022
Q3 		$1K Buy
+3
New +$467 ﹤0.01% 1576

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

MassMutual Private Wealth & Trust's KLRS Position: Q4 2022 in Review

MassMutual Private Wealth & Trust sold out of Kalaris Therapeutics (KLRS) in Q4 2022, closing a stake of 3 shares — an estimated $1K sold.

MassMutual Private Wealth & Trust first reported a position in KLRS in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 85 funds tracked by Wall St. Rank hold KLRS as of Q4 2022.

  • MassMutual Private Wealth & Trust reported no remaining Kalaris Therapeutics position as of Q4 2022 after selling out during the quarter.
  • MassMutual Private Wealth & Trust sold 3 Kalaris Therapeutics shares in Q4 2022, an estimated $1K.
  • MassMutual Private Wealth & Trust first reported a position in Kalaris Therapeutics in Q3 2022 and held it in 1 quarter.
  • MassMutual Private Wealth & Trust's Kalaris Therapeutics position peaked at $1K in Q3 2022.
  • 85 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2022.

Based on MassMutual Private Wealth & Trust's 13F filing for Q4 2022, filed 6 Jan 2023.